Literature DB >> 12760820

A Tuberculosis Treatment Completion Trial.

Michael S. Simberkoff1.   

Abstract

Entities:  

Year:  2003        PMID： 12760820     DOI： 10.1007/s11908-003-0081-z

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN： 1523-3847            Impact factor:   3.725


× No keyword cloud information.
  2 in total

1.  A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen.

Authors:  D L Cohn; B J Catlin; K L Peterson; F N Judson; J A Sbarbaro
Journal:  Ann Intern Med       Date:  1990-03-15       Impact factor: 25.391

2.  Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium.

Authors:  A Vernon; W Burman; D Benator; A Khan; L Bozeman
Journal:  Lancet       Date:  1999-05-29       Impact factor: 79.321
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.